Which Lactobacillus Probiotic Is the Best?
Probiotics have become an important component of modern nutritional science, microbiome research, and functional health product development. Among the most extensively studied probiotic microorganisms are bacteria belonging to the Lactobacillus group, which are widely used in dietary supplements, fermented foods, functional beverages, and specialized nutritional formulations.
However, one important question continues to attract considerable attention from consumers, healthcare professionals, researchers, and supplement manufacturers:
Which Lactobacillus probiotic is the best?
The answer is more complex than selecting a single bacterial species. Different Lactobacillus strains have been investigated for different physiological functions, including digestive health, intestinal barrier support, immune modulation, vaginal microbiome health, infant digestive comfort, and other areas of human health research.
Scientific evidence demonstrates that probiotic efficacy is often both strain-specific and condition-specific. A Lactobacillus strain that has demonstrated benefits in one clinical application may not necessarily provide the same benefits in another. This distinction is particularly important when comparing probiotic products, interpreting clinical studies, or developing scientifically supported probiotic formulations.
Consequently, the best Lactobacillus probiotic should not be defined as the microorganism with the highest popularity, the greatest number of species, or the highest colony-forming unit (CFU) count. Instead, it should be identified according to its clinical evidence, strain identity, intended application, safety profile, formulation characteristics, and manufacturing quality.
This article examines the leading Lactobacillus probiotic strains, their scientific evidence, potential applications, comparative advantages, and considerations for selecting an appropriate probiotic.
Understanding Lactobacillus Probiotics
Lactobacillus is historically one of the most recognized genera of beneficial bacteria associated with fermented foods and probiotic products.
These microorganisms are generally characterized as Gram-positive, rod-shaped bacteria, with many species capable of producing lactic acid through carbohydrate fermentation.
Lactobacillus-associated microorganisms are found in different ecological environments, including:
The gastrointestinal tract.
The vaginal microbiome.
The oral microbiome.
Fermented dairy products.
Fermented vegetables and other foods.
Specialized probiotic formulations.
They have attracted scientific interest because certain strains may interact with the host through multiple mechanisms, including microbial competition, production of organic acids, interaction with intestinal epithelial cells, modulation of immune signalling, and effects on the intestinal environment.
Important taxonomic clarification
In 2020, the scientific classification of the former Lactobacillus genus underwent a major revision. Several organisms previously identified as Lactobacillus were reassigned to new genera.
For example:
Former name | Current name |
Lactobacillus rhamnosus | Lacticaseibacillus rhamnosus |
Lactobacillus casei | Lacticaseibacillus casei |
Lactobacillus paracasei | Lacticaseibacillus paracasei |
Lactobacillus plantarum | Lactiplantibacillus plantarum |
Lactobacillus reuteri | Limosilactobacillus reuteri |
Lactobacillus acidophilus | Lactobacillus acidophilus |
These changes reflect improved understanding of bacterial evolutionary relationships. The older names remain widely used in clinical publications, commercial probiotic products, and scientific databases.
For consistency, this article primarily uses the familiar historical names while acknowledging the revised nomenclature where relevant.
The taxonomic revision is described in the landmark scientific publication Zheng et al., 2020, International Journal of Systematic and Evolutionary Microbiology.
Why There Is No Single Best Lactobacillus Probiotic
The concept of a universal best probiotic is scientifically misleading.
A probiotic strain may demonstrate benefits for one application but show limited or inconsistent results for another. For example, Lactobacillus rhamnosus GG has been extensively studied in gastrointestinal applications, whereas Lactobacillus plantarum has attracted considerable interest in research involving irritable bowel syndrome.
Similarly, Lactobacillus reuteri has been investigated in infantile colic, while Lactobacillus crispatus has been studied in relation to vaginal microbiome health.
These organisms cannot be considered interchangeable merely because they belong to the same broad probiotic category.
A systematic review examining probiotic strain specificity included 228 clinical trials and found evidence that probiotic efficacy varies according to the specific strain and clinical indication. The researchers emphasized that combining results from different probiotic strains may produce misleading conclusions [1].
What determines whether a Lactobacillus strain is effective?
The scientific evaluation of a probiotic generally considers:
Exact strain identification.
Evidence from randomized controlled trials.
The population studied.
The health outcome investigated.
The dosage and duration used.
The formulation and delivery system.
Viability and stability throughout shelf life.
Safety and suitability for the intended population.
Therefore, the best Lactobacillus probiotic is the strain with the most relevant and reliable evidence for a particular application.
Top Lactobacillus Probiotic Strains: A Comparative Overview
The following strains are particularly relevant when evaluating evidence-based probiotic applications.
Probiotic strain | Primary research area | Scientific relevance |
Lactobacillus rhamnosus GG | Gastrointestinal health | Extensive clinical research |
Lactobacillus plantarum | IBS and digestive symptoms | Clinical trials in IBS populations |
Lactobacillus reuteri | Infantile colic | Clinical trials in breastfed infants |
Lactobacillus acidophilus (NCFM, DDS-1) | Digestive health | Human clinical research |
Lactobacillus crispatus | Vaginal microbiome | Clinical studies of vaginal microbiota |
Lactobacillus casei | Antibiotic-associated diarrhea research | Evidence for specific formulations |
Lactobacillus helveticus | Gastrointestinal and immune research | Often studied in combinations |
Lactobacillus paracasei | Digestive and immune research | Evidence varies by strain |
The table identifies research areas rather than guaranteeing therapeutic efficacy. Evidence for one strain must not be transferred automatically to another strain of the same species.

Lactobacillus rhamnosus GG (LGG): One of the Most Extensively Studied Probiotics
Strain identification
Genus: Lacticaseibacillus
Species: rhamnosus
Strain designation: GG
Common historical name: Lactobacillus rhamnosus GG
Lactobacillus rhamnosus GG, commonly abbreviated LGG, is among the most extensively investigated probiotic strains in human clinical research.
It has been studied in children and adults across multiple gastrointestinal applications, including antibiotic-associated diarrhea, acute infectious diarrhea, and other digestive health outcomes.
Why is LGG important?
LGG has several characteristics that have contributed to its scientific interest:
A substantial body of human clinical research.
Well-characterized strain identity.
Research on intestinal epithelial interactions.
Investigation of microbial competition.
Studies involving immune signalling.
Research on gastrointestinal symptoms and diarrhoea-related outcomes.
LGG has also been investigated for its ability to interact with intestinal epithelial surfaces and influence the local intestinal environment.
These biological observations help explain its scientific relevance, although laboratory mechanisms do not automatically establish clinical benefits.
LGG and antibiotic-associated diarrhea
Antibiotic-associated diarrhea is one of the major applications investigated for LGG.
Antibiotics may disrupt the normal intestinal microbial ecosystem. This disruption can affect intestinal metabolism, microbial competition, and gastrointestinal function.
Some probiotic interventions have been studied for their ability to reduce the occurrence of antibiotic-associated diarrhea.
The systematic review examining strain-specific probiotic efficacy identified evidence supporting LGG for selected pediatric antibiotic-associated diarrhea prevention outcomes. However, its effectiveness varied across clinical indications and was not universal [1].
LGG and gastrointestinal health
LGG is also frequently studied in relation to:
Acute infectious diarrhea.
Gastrointestinal microbial balance.
Intestinal barrier interactions.
Immune system signaling.
Digestive health in children.
It is important to distinguish evidence for prevention from evidence for treatment. A strain that demonstrates a preventive effect in a specific population may not necessarily provide the same effect after a condition has developed. For a wider look at probiotics for gastrointestinal issues, see our dedicated guide.
Is LGG the best Lactobacillus probiotic?
LGG is a strong candidate when evaluating probiotics with substantial gastrointestinal clinical research.
Nevertheless, it is not universally superior to other Lactobacillus strains. The appropriate choice depends on the targeted health outcome, population, and evidence supporting the specific formulation.
Scientific assessment: LGG is one of the leading reference strains for gastrointestinal probiotic research, particularly when evidence for a specific diarrhea-related application is relevant.

Lactobacillus plantarum: A Leading Strain in IBS Research
Strain identification
Genus: Lactiplantibacillus
Species: plantarum
Historical name: Lactobacillus plantarum
Lactobacillus plantarum, commonly abbreviated LP, is one of the prominent probiotic strains studied in relation to irritable bowel syndrome (IBS).
IBS is a functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and changes in bowel habits.
Why has LP attracted attention?
The strain has been investigated for several mechanisms and clinical outcomes:
Interaction with intestinal mucosal surfaces.
Gastrointestinal symptom improvement.
Effects on abdominal discomfort.
Effects on bloating.
Digestive comfort.
Potential modulation of the intestinal environment.
A key area of research involves the interaction of LP with intestinal epithelial structures, including its association with mannose-binding mechanisms.
These observations provide mechanistic context for studying its effects in gastrointestinal disorders.
LP and irritable bowel syndrome
LP has been evaluated in randomized clinical trials involving individuals with IBS.
Some studies have reported improvements in selected IBS symptoms, particularly abdominal pain and bloating. However, outcomes vary among studies, and the magnitude of benefit is not uniform.
A probiotic's effect on IBS may depend on:
The IBS subtype.
Baseline symptom severity.
The duration of supplementation.
The outcome measurement used.
Study design and statistical power.
Individual microbiome characteristics.
Therefore, LP should be evaluated according to the clinical evidence for its specific application rather than assuming it treats every IBS symptom [4].
Is LP better than LGG?
Neither strain can be declared universally better.
LP is especially relevant when evaluating probiotic research involving IBS-related symptoms. LGG has a broader clinical research history in several gastrointestinal applications, including diarrhea-related outcomes.
Their scientific value depends on the specific application.
Scientific assessment: LP is an important strain to consider in evidence-based IBS-oriented probiotic research.
Lactobacillus reuteri: A Prominent Probiotic for Infantile Colic Research
Strain identification
Genus: Limosilactobacillus
Species: reuteri
Historical name: Lactobacillus reuteri
Lactobacillus reuteri is a well-characterized probiotic strain that has received substantial attention in infant gastrointestinal research.
Its most recognized clinical application is the investigation of infantile colic, particularly in breastfed infants.
What is infantile colic?
Infantile colic is characterized by prolonged crying or fussing in otherwise healthy infants. Although the precise mechanisms are not fully understood, several factors have been investigated, including gastrointestinal function, microbial composition, and infant development.
Researchers have explored whether probiotic supplementation may influence crying duration and digestive comfort.
Clinical research on L. reuteri
A randomized, double-blind, placebo-controlled trial involving 50 exclusively breastfed infants investigated L. reuteri at a daily dose of 10⁸ CFU for 21 days.
The study reported a greater reduction in crying time in the probiotic group compared with placebo. The proportion of infants achieving a 50% reduction in crying time was also higher in the probiotic group [5].
A subsequent randomized study involving 80 predominantly breastfed infants also reported benefits in selected colic outcomes.
However, an important larger community-based trial involving 167 infants, including breastfed and formula-fed infants, found that L. reuteri did not provide an overall benefit in reducing crying or fussing. The study also reported differences according to feeding type [5].
What do these findings mean?
The available evidence suggests that the potential effects of L. reuteri may depend on the infant population and feeding characteristics.
This illustrates a fundamental principle of probiotic science: findings from one population cannot automatically be generalized to every population.
Scientific assessment: L. reuteri is an important Lactobacillus-associated strain for infantile colic research, but its use should be considered in the context of pediatric guidance and individual clinical circumstances.
Lactobacillus acidophilus: A Major Probiotic Species with Multiple Research Strains
Lactobacillus acidophilus is one of the most widely recognized probiotic species in the global nutritional supplement industry.
It has been incorporated into:
Probiotic capsules.
Powder sachets.
Fermented dairy products.
Functional foods.
Multi-strain probiotic blends.
Specialized gastrointestinal formulations.
However, an important scientific distinction must be made: Lactobacillus acidophilus is a species, not a single probiotic strain.
Different strains may possess different functional characteristics and clinical evidence.
Lactobacillus acidophilus NCFM
NCFM is a well-characterized strain with a long history of research involving gastrointestinal health.
Its scientific investigations include:
Intestinal epithelial interactions.
Digestive function.
Immune-related mechanisms.
Abdominal bloating.
Functional bowel disorders.
IBS-related outcomes.
A randomized clinical study investigated L. acidophilus NCFM in adults with IBS using two different doses over 12 weeks.
Although symptom scores improved during the study, the results did not demonstrate significant differences between the probiotic groups and placebo for the primary outcome [6].
Lactobacillus acidophilus DDS-1
DDS-1 is another strain studied in gastrointestinal health.
A randomized, double-blind clinical trial involving adults with IBS investigated L. acidophilus DDS-1 at 10¹⁰ CFU/day for six weeks.
The study reported improvements in abdominal pain severity and IBS symptom severity compared with placebo. However, these findings apply to the specific strain, dose, study design, and population investigated [7].
Why acidophilus remains important
Lactobacillus acidophilus continues to be relevant in probiotic formulation development because:
It is extensively characterized.
Multiple strains have human research.
It is compatible with several probiotic delivery formats.
It has a long history of use in fermented foods.
It can be incorporated into single-strain or multi-strain products.
Nevertheless, selecting an acidophilus strain should always involve evaluation of its specific clinical evidence rather than relying on species-level familiarity.
Scientific assessment: L. acidophilus is a major probiotic species with useful strain-specific research programs. NCFM and DDS-1 illustrate how evidence can differ between strains even within the same species.
Lactobacillus crispatus: A Specialized Strain for Vaginal Microbiome Research
Strain identification
Genus: Lactobacillus
Species: crispatus
Research formulation: LACTIN-V
Lactobacillus crispatus is a specialized probiotic strain investigated in vaginal microbiome research.
Unlike gastrointestinal probiotic strains that are typically administered orally, has been studied as a vaginally administered live biotherapeutic.
Why is L. crispatus important?
The vaginal microbiome is a distinct microbial ecosystem.
In many reproductive-age women, Lactobacillus species are important members of the vaginal microbial community. Certain Lactobacillus-dominant microbiome states are associated with lower vaginal pH and reduced abundance of several bacterial taxa linked to bacterial vaginosis.
L. crispatus is particularly relevant because it is frequently associated with a Lactobacillus-dominant vaginal environment.
Its research has examined:
Vaginal microbiota composition.
Microbial community restoration.
Bacterial vaginosis recurrence.
Vaginal microbial colonization.
Genital inflammatory biomarkers.
LACTIN-V clinical research
A randomized, double-blind, placebo-controlled phase 2b trial evaluated Lactobacillus crispatus in women who had completed treatment for bacterial vaginosis.
The trial enrolled 228 participants and investigated the recurrence of bacterial vaginosis following treatment with vaginal metronidazole.
The results showed a lower recurrence rate in the LACTIN-V group than in the placebo group by the primary follow-up endpoint [8].
A more recent phase 2 study conducted in South Africa investigated LACTIN-V and vaginal microbiota among women at high risk of HIV acquisition. It reported increased detection of L. crispatus-dominant microbiomes in the intervention group at an early follow-up point, although the sample was small and the findings do not establish HIV prevention efficacy [9].
Is L. crispatus the best Lactobacillus probiotic?
For specialized vaginal microbiome research, L. crispatus is a particularly important strain.
However, it should not be treated as an interchangeable oral probiotic or as a general solution for all women's health conditions.
Scientific assessment: L. crispatus is a leading specialized Lactobacillus strain for vaginal microbiome research and is supported by clinical investigations of a specific vaginal formulation.

Lactobacillus casei: A Probiotic Species With Important Formulation-Specific Evidence
Lactobacillus casei, now classified as Lacticaseibacillus casei, is another species used in probiotic formulations.
Several strains have been investigated in gastrointestinal applications.
One historically important example is L. casei, which has been evaluated in research involving antibiotic-associated diarrhea.
Research involving probiotic mixtures containing L. casei or related Lactobacillus strains also highlights the importance of formulation-specific evidence.
For example, one three-strain preparation involving:
L. acidophilus
L. casei
L. rhamnosus
has been studied in antibiotic-associated diarrhea prevention.
The clinical findings associated with this mixture cannot be attributed independently to each microorganism without appropriate evidence [1].

Lactobacillus helveticus and Lactobacillus paracasei: Research-Oriented Probiotic Species
Lactobacillus helveticus and Lactobacillus paracasei are also used in probiotic research and commercial formulations.
Lactobacillus helveticus
L. helveticus has been studied in:
Fermented dairy applications.
Gastrointestinal research.
Microbial metabolism.
Multi-strain probiotic combinations.
Selected immune-related investigations.
Some formulations combine L. helveticus with L. rhamnosus.
A frequently discussed combination is L. helveticus and L. rhamnosus.
The scientific evidence associated with such a combination should be evaluated as a specific formulation rather than as evidence that every L. helveticus strain has equivalent effects.
Lactobacillus paracasei
L. paracasei has been investigated in:
Gastrointestinal microbial interactions.
Immune-related research.
Fermented food applications.
Digestive health formulations.
Multi-strain probiotic preparations.
As with other Lactobacillus species, clinical effects depend on the strain and the outcome investigated.
Scientific assessment: Both species offer relevant opportunities for probiotic research and formulation development, but their selection should be guided by strain-specific clinical evidence.
Comparative Ranking: Which Lactobacillus Probiotic Is Best for Different Applications?
The following comparison provides a practical scientific framework for selecting Lactobacillus strains.
This is an application-based comparison, not a universal clinical efficacy ranking.
Application | Important Lactobacillus strain | Evidence perspective |
Pediatric antibiotic-associated diarrhea | L. rhamnosus GG | Substantial clinical evidence for selected outcomes |
IBS symptom research | L. plantarum | Multiple clinical studies, with variable results |
Infantile colic research | L. reuteri | Evidence particularly relevant to breastfed infants |
Abdominal pain in IBS | L. acidophilus DDS-1 | Positive findings in a specific RCT |
Vaginal microbiome research | L. crispatus | Specialized clinical evidence |
Bloating research | L. acidophilus NCFM | Investigated alone and in combinations |
Antibiotic-associated diarrhea | Specific L. casei-containing formulations | Evidence applies to studied strain/formulation |
Fermented food applications | L. acidophilus, L. casei, L. plantarum | Technological and nutritional relevance |
Important interpretation
This comparison does not establish that the strains are interchangeable or that the listed outcomes represent approved treatment indications.
The World Gastroenterology Organisation Global Guidelines on Probiotics and Prebiotics emphasize that clinical decisions should be based on evidence for specific strains or combinations, including the indication and dose studied. The guideline does not provide a universal ranking of probiotics by efficacy [10].
How Lactobacillus Probiotics May Work in the Human Body
The biological mechanisms of Lactobacillus probiotics are diverse and may differ considerably among strains.
It is useful to distinguish between mechanisms observed in laboratory studies and clinical outcomes demonstrated in humans.
Interaction with the intestinal microbiota
Certain Lactobacillus strains may influence the intestinal microbial environment through competition for nutrients, microbial interactions, and production of metabolites.
These mechanisms may affect the ecological relationships among microorganisms in the gastrointestinal tract.
However, probiotic supplementation does not necessarily produce permanent colonization or permanently restructure the microbiome.
Human studies indicate that probiotic colonization and persistence vary according to the probiotic strain and the individual host environment [16].
Production of organic acids
Many Lactobacillus strains produce lactic acid through carbohydrate fermentation.
Organic acid production may influence local pH and microbial competition.
In selected environments, these changes can affect the growth conditions of other microorganisms.
The magnitude and significance of these effects depend on the strain, substrate availability, environment, and microbial community.
Interaction with intestinal epithelial cells
Some Lactobacillus strains have been investigated for their interactions with intestinal epithelial cells.
These studies have explored:
Epithelial signaling.
Barrier-related processes.
Cellular responses.
Microbial adhesion.
Host–microbe communication.
For example, research involving LGG has examined interactions between probiotic-derived factors and intestinal epithelial cells.
Such findings are important in understanding potential biological activity, but they should not be interpreted as proof that all Lactobacillus probiotics repair intestinal permeability or treat intestinal disorders.
Immune signaling
Lactobacillus strains may interact with immune-related pathways through microbial components and metabolites.
Scientific investigations include:
Cytokine signaling.
Immune-cell interactions.
Host response modulation.
Mucosal immune mechanisms.
The direction and magnitude of immune responses may vary among strains.
Consequently, the phrase “boosts immunity” is too broad to describe all Lactobacillus probiotics scientifically.
Microbial metabolite interactions
Some probiotic strains may influence the intestinal environment through microbial metabolites.
Potential mechanisms include:
Lactic acid production.
Changes in fermentation activity.
Interactions with other microbial metabolic pathways.
Effects on local pH.
Microbial competition.
These mechanisms are an important area of microbiome research [11].
What Is the Difference Between a Lactobacillus Species and a Probiotic Strain?
This is one of the most important questions for understanding probiotic science.
A probiotic strain is identified by its genus, species, and specific strain designation.
For example:
Level | Example |
Genus | Lactobacillus |
Species | rhamnosus |
Strain | GG |
Example: Lactobacillus rhamnosus GG
Two strains belonging to the same species may differ in:
Genetic characteristics.
Metabolic properties.
Adhesion characteristics.
Antimicrobial activity.
Functional behavior.
Clinical research evidence.
Stability and technological characteristics.
For example, evidence for L. rhamnosus GG cannot automatically be transferred to another L. rhamnosus strain.
This distinction has major implications for probiotic product development and scientific communication.
How to Select the Best Lactobacillus Probiotic Supplement
Selecting a probiotic product requires more than reading the species name on a label.
The following considerations are particularly important.
Check the exact strain designation
A high-quality probiotic label should identify the microorganism clearly.
For example:
L. rhamnosus GG.
L. plantarum.
L. reuteri.
L. acidophilus NCFM.
A label that only states “Lactobacillus blend” provides limited information about the specific microorganisms included.
Evaluate the evidence for the intended application
Look for clinical studies involving:
The same strain.
A similar dosage.
The relevant population.
The same health outcome.
A comparable formulation.
Evidence from a different strain should not be considered equivalent.
Evaluate the CFU count
CFU refers to colony-forming units, a measure used to estimate viable microorganisms capable of forming colonies under specified laboratory conditions.
A higher CFU count does not automatically mean better efficacy.
The scientifically relevant dose is the dose evaluated for the particular strain and application.
For example, some clinical studies have investigated LGG at doses in the billions of CFU per day, whereas certain infant probiotic trials have used 10⁸ CFU/day.
These examples are not interchangeable dosage recommendations.
Check viability through shelf life
Probiotic viability may decrease during storage. Learn more about how Lactobacillus probiotics should be stored.
Important formulation factors include:
Moisture exposure.
Temperature.
Oxygen exposure.
Packaging.
Storage conditions.
Carrier ingredients.
Manufacturing process.
A product should provide an appropriate viable count through the stated shelf life, rather than relying solely on the count at manufacture.
Consider the delivery format
Probiotic delivery systems include:
Capsules.
Powder sachets.
Tablets.
Stick packs.
Fermented beverages.
Dairy-based products.
Specialized liquid formulations.
The best delivery system depends on the strain's stability, intended use, consumer requirements, and manufacturing capabilities.
Review product quality and safety
Consumers should consider:
Manufacturer credibility.
Quality control.
Ingredient traceability.
Strain authentication.
Appropriate storage instructions.
Clear labeling.
Regulatory compliance.
For vulnerable populations, particularly premature infants, critically ill patients, or people with significant immunocompromise, probiotic use should be discussed with an appropriate healthcare professional.
Lactobacillus Probiotics: Safety, Regulatory Considerations, and Scientific Limitations
Although Lactobacillus strains are commonly used in food and supplement products, probiotic safety should not be assumed to be identical across all microorganisms and populations.
General safety
Many established Lactobacillus probiotic strains have a favorable safety history in generally healthy populations.
However, rare invasive infections involving organisms used in probiotic products have been reported, particularly in medically vulnerable individuals.
A clinical review of probiotic safety highlighted the importance of strain selection, appropriate risk assessment, and monitoring for rare adverse events [12].
Vulnerable populations
Additional medical caution is appropriate for:
Premature infants.
Critically ill patients.
Patients with central venous catheters.
Individuals with severe immunocompromise.
Patients with major intestinal barrier disruption.
Certain hospitalized populations.
The decision to use probiotics in these groups should be individualized.
EFSA and probiotic safety assessment
The European Food Safety Authority maintains a Qualified Presumption of Safety (QPS) framework for microorganisms used in relevant food and feed regulatory assessments.
The framework considers aspects such as taxonomic identity, safety concerns, and qualifications applicable to microorganisms.
However, QPS status is not equivalent to proof of clinical efficacy.
It should not be interpreted as:
A universal probiotic approval.
Proof that a strain treats a medical condition.
A guarantee that every commercial formulation is safe.
Automatic authorization of a health claim.
EFSA also clarifies that human probiotics are not automatically assessed under QPS merely because they are marketed as probiotics. The applicable regulatory framework depends on the product and intended use [13].
EFSA health claims and scientific evidence
A microorganism's safety status and its clinical efficacy are separate scientific questions.
For example, a probiotic may have a favorable safety assessment but lack sufficient evidence for a particular health claim.
Health claims should therefore be evaluated according to the relevant jurisdiction, scientific evidence, and applicable regulatory requirements.
Lactobacillus Probiotics and the Future of Precision Microbiome Science
The future of probiotic research is increasingly focused on precision rather than broad species-based recommendations.
Researchers are investigating how probiotic effects may depend on:
Individual microbiome composition.
Host genetics.
Dietary patterns.
Age.
Baseline microbial ecology.
Disease phenotype.
Strain-specific metabolic characteristics.
This approach may help improve the design of future probiotic products and clinical studies.
Precision probiotic formulation
Future probiotic formulations may increasingly incorporate:
Carefully selected strain combinations.
Evidence-based dosage selection.
Targeted delivery technologies.
Improved stability systems.
Better characterization of microbial interactions.
More precise clinical outcome assessment.
Personalized microbiome research
Personalized probiotic research aims to understand why the same probiotic may produce different responses in different individuals.
This is particularly relevant to IBS, where symptom patterns and underlying biological characteristics vary substantially.
Next-generation probiotic development
Research is also exploring microorganisms and microbial-derived products beyond conventional Lactobacillus strains.
These include:
Next-generation live biotherapeutics.
Defined microbial consortia.
Postbiotic preparations.
Microbial metabolites.
Precision synbiotic formulations.
Such developments expand the scientific possibilities of microbiome-based nutritional and therapeutic research.
ClinicalTrials.gov as a research resource
ClinicalTrials.gov provides a useful platform for investigating ongoing and completed probiotic studies.
Researchers and product developers can review:
Trial objectives.
Study populations.
Intervention details.
Primary outcomes.
Recruitment status.
Trial registration.
Results when available.
Swiss Medicare Probiotics: Your Lactobacillus Probiotics Manufacturer
As a Lactobacillus manufacturer for supplement, functional food and private-label brands, Swiss Medicare Probiotics supplies bulk Lactobacillus probiotics, including L. rhamnosus, L. plantarum, L. acidophilus, L. casei, L. paracasei, L. reuteri and L. helveticus, along with probiotic blends and custom formulation support. If you are looking for a Lactobacillus probiotics manufacturer, contact our team for specifications and a quotation.
Related Reading
Frequently Asked Questions
1. Which Lactobacillus probiotic is the best overall?
There is no universally best Lactobacillus probiotic.
Lactobacillus rhamnosus GG is one of the most extensively studied strains for gastrointestinal health. Lactobacillus plantarum is an important strain in IBS research, while Lactobacillus reuteri has been investigated for infantile colic.
The best strain depends on the intended application and the strength of its clinical evidence.
2. Which Lactobacillus probiotic is best for gut health?
L. rhamnosus GG, L. plantarum, and selected L. acidophilus strains are important candidates in gastrointestinal research.
However, gut health includes multiple outcomes, such as digestive comfort, bowel function, intestinal microbial balance, and gastrointestinal symptoms. Different strains may have different effects.
3. Which Lactobacillus is best for IBS?
L. plantarum and L. acidophilus DDS-1 are among the strains investigated in IBS clinical research.
Some studies have reported improvements in abdominal pain, bloating, or overall symptom scores. Other trials have reported results that were not significantly different from placebo.
Consequently, neither strain can be considered a guaranteed treatment for IBS.
4. Is Lactobacillus rhamnosus GG better than Lactobacillus plantarum?
Not universally.
LGG has substantial clinical research involving diarrhea-related outcomes and other gastrointestinal applications.
LP has important clinical research involving IBS symptoms.
The two strains should be compared according to their intended application rather than their overall popularity.
5. Is Lactobacillus acidophilus a good probiotic?
L. acidophilus is a well-established probiotic species with several extensively characterized strains.
NCFM and DDS-1 are examples of strains with human clinical research.
However, the evidence for one strain cannot automatically be applied to all L. acidophilus products.
6. Which Lactobacillus is best for women's health?
L. crispatus is an important strain in vaginal microbiome research.
It has been studied in a specialized vaginal formulation for bacterial vaginosis recurrence.
It should not be confused with general oral probiotics or considered a treatment for every women's health condition.
7. Which Lactobacillus is best for infantile colic?
L. reuteri has been investigated extensively in infantile colic.
Some studies have reported improvements in crying duration among breastfed infants, while other studies have reported no overall benefit.
Probiotic use in infants should be discussed with a pediatric healthcare professional.
8. Does a higher CFU count mean a better probiotic?
No.
A higher CFU count does not automatically indicate greater clinical efficacy.
The relevant dosage depends on the specific strain, formulation, population, and clinical outcome investigated.
9. Are multi-strain Lactobacillus probiotics better than single-strain probiotics?
Not necessarily.
Some multi-strain formulations have clinical evidence supporting specific applications, while some single-strain probiotics have substantial research evidence.
The number of strains does not automatically determine efficacy.
10. Can Lactobacillus probiotics permanently colonize the gut?
Not necessarily.
Many orally administered probiotics have transient effects or temporary persistence in the gastrointestinal tract.
Colonization depends on the strain and individual host factors.
11. Are Lactobacillus probiotics safe for everyone?
Many established probiotic strains have favorable safety records in healthy populations.
However, medically vulnerable individuals, premature infants, and critically ill patients require additional caution and professional guidance.
12. Are Lactobacillus probiotics approved by EFSA?
EFSA evaluates microorganisms and health claims under applicable European regulatory frameworks.
A microorganism's safety assessment does not automatically establish clinical efficacy or authorize a health claim.
13. Can Lactobacillus probiotics be combined with prebiotics?
Yes. Probiotic microorganisms can be formulated with prebiotic ingredients in synbiotic products.
However, a synbiotic formulation should be evaluated according to the specific microorganisms, prebiotic ingredients, intended function, and supporting evidence.
14. What is the difference between Lactobacillus and Bifidobacterium?
Both are important groups of microorganisms used in probiotic products.
They differ in taxonomy, physiological characteristics, and metabolic properties.
Some formulations combine Lactobacillus and Bifidobacterium strains to investigate complementary effects.
15. How should manufacturers select Lactobacillus strains for probiotic formulation development?
Manufacturers should evaluate:
Strain-specific clinical evidence.
Intended health application.
Strain identity and authentication.
Safety characteristics.
Viability and stability.
Manufacturing compatibility.
CFU requirements.
Regulatory considerations.
Product delivery format.
Clinical evidence should guide formulation development rather than relying exclusively on marketing trends.
Scientific References
[1] McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. PubMed | PubMed Central full text
[2] Choosing an Appropriate Probiotic Product for Your Patient: An Evidence-Based Practical Guide. PubMed | PubMed Central full text
[3] Lactobacillus rhamnosus GG in gastrointestinal research. PubMed search | ClinicalTrials.gov
[4] Ducrotté P, Sawant P, Jayanthi V. Clinical Trial: Lactobacillus plantarum Improves Symptoms of Irritable Bowel Syndrome. PubMed | PubMed Central full text
[5] Savino F, et al. Lactobacillus reuteri in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial. PubMed | Community-based trial: PubMed
[6] Irritable Bowel Syndrome Symptom Severity Improves Equally with Probiotic and Placebo (L. acidophilus NCFM). PubMed
[7] Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome. PubMed | PubMed Central full text
[8] Cohen CR, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. PubMed
[9] LACTIN-V and Vaginal Microbiota and Genital Inflammation. PubMed | PubMed Central
[10] World Gastroenterology Organisation. Global Guidelines: Probiotics and Prebiotics. Official WGO Guidelines
[11] NIH Office of Dietary Supplements. Probiotics: Health Professional Fact Sheet. NIH ODS
[12] Borriello SP, et al. Safety of Probiotics That Contain Lactobacilli or Bifidobacteria. PubMed
[13] European Food Safety Authority. Qualified Presumption of Safety (QPS). EFSA QPS Framework
[14] Mejía-Caballero A, Marco ML. Lactobacilli Biology, Applications and Host Interactions. Nature Reviews Microbiology. Nature Reviews Microbiology | PubMed
[15] Van Rossum T, Ferretti P, Maistrenko OM, et al. Diversity Within Species: Interpreting Strains in Microbiomes. Nature Reviews Microbiology
[16] Zmora N, et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. 2018. PubMed



Comments